RESTORE partners from the Charité Universitätsmedizin Berlin have published a perspective article in Frontiers in Immunology (Vaccines and Molecular Therapeutics) about the use of mesenchymal stromal/stem cell (MSC) therapies for treating COVID-19. Within the article they discuss the risks and issues that should be considered when administering MSC products to COVID-19 patients for maximum treatment safety and efficacy.

To read in detail and find out their three key recommendations for the use of MSC products please read the full article:

Read the full article